CA
NZ
UK
AU
IND
US
…
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Abeona Therapeutics is a clinical-stage biopharmaceutical company developing gene and cell therapies for rare genetic and orphan diseases. Long-term growth may be driven by successful clinical trial results, regulatory approvals and licensing or commercialization of one-time therapies that address high unmet medical need. The company may benefit from platform technologies that could support multiple indications and partnerships to scale development.
Material investment risks include clinical and regulatory failure, high cash burn with likely need for additional financing, complex manufacturing and scale-up challenges, and competition from other gene-therapy developers.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 71.28M | -63.73M | -54.19M | -39.70M | -84.94M |
| Net income | 71.18M | -63.73M | -54.19M | -31.81M | -88.61M |
| Selling general administrative | 65.03M | 29.85M | 19.00M | 17.26M | 22.80M |
| Selling and marketing expenses | - | - | 1.59M | - | - |
| Gross profit | 4.29M | -2.91M | 1.90M | 0.96M | 3.00M |
| Reconciled depreciation | 3.56M | 2.91M | 3.20M | 4.58M | 3.25M |
| Ebit | 75.02M | -59.53M | -53.77M | -45.26M | -89.84M |
| Ebitda | 78.59M | -56.62M | -50.57M | -44.69M | -54.05M |
| Depreciation and amortization | 3.56M | 2.91M | 3.20M | 0.57M | 35.78M |
| Operating income | -89.45M | -64.21M | -47.13M | -45.26M | -89.84M |
| Other operating expenses | 95.27M | 64.21M | 50.63M | 46.67M | 60.37M |
| Interest expense | 3.74M | 4.21M | 0.42M | 0.74M | 3.67M |
| Tax provision | 0.10M | 0.00M | - | - | - |
| Interest income | 5.56M | 4.25M | 2.12M | 0.43M | 0.07M |
| Net interest income | 1.82M | 0.04M | 1.70M | -0.30M | -3.60M |
| Income tax expense | 0.10M | - | 3.03M | -7.89M | 3.67M |
| Total revenue | 5.82M | 0.00M | 3.50M | 1.41M | 3.00M |
| Total operating expenses | 93.74M | 61.30M | 49.03M | 46.22M | 60.37M |
| Cost of revenue | 1.53M | 2.91M | 1.60M | 0.45M | - |
| Total other income expense net | 160.73M | 0.48M | -7.05M | 5.56M | 4.90M |
| Net income from continuing ops | 71.18M | -63.73M | -54.19M | -39.70M | -84.94M |
| Net income applicable to common shares | - | - | - | -43.48M | -84.94M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 219.57M | 108.93M | 64.00M | 64.21M | 79.59M |
| Intangible assets | - | - | - | - | 1.38M |
| Other current assets | 1.29M | 1.48M | 0.73M | 0.42M | 7.38M |
| Total liab | 60.35M | 64.90M | 49.18M | 37.45M | 28.21M |
| Total stockholder equity | 159.22M | 44.03M | 14.83M | 26.76M | 51.38M |
| Other current liab | 8.60M | 6.40M | 10.57M | 4.20M | 10.18M |
| Common stock | 0.55M | 0.46M | 0.27M | 0.18M | 1.47M |
| Capital stock | 0.55M | 0.46M | 0.27M | 0.18M | 1.47M |
| Retained earnings | -742.08M | -813.26M | -749.52M | -695.34M | -655.64M |
| Other liab | - | - | - | 23.82M | 4.03M |
| Good will | - | - | - | - | 0.00M |
| Other assets | - | - | - | 0.04M | 1.06M |
| Cash | 78.44M | 23.36M | 14.81M | 14.22M | 32.94M |
| Total current liabilities | 29.57M | 16.59M | 13.42M | 7.78M | 16.62M |
| Current deferred revenue | - | - | - | - | 0.30M |
| Net debt | -53.47M | -0.31M | -9.41M | -6.59M | -23.56M |
| Short term debt | 13.09M | 6.75M | 1.00M | 1.77M | 1.82M |
| Short long term debt | 12.22M | 5.93M | - | - | - |
| Short long term debt total | 24.97M | 23.05M | 5.40M | 7.63M | 9.38M |
| Other stockholder equity | 900.60M | 856.82M | 764.15M | 722.05M | 705.57M |
| Property plant equipment | - | - | - | 11.07M | 21.74M |
| Total current assets | 204.91M | 100.85M | 55.74M | 53.10M | 55.40M |
| Net tangible assets | - | - | - | 26.76M | 49.99M |
| Short term investments | 112.97M | 74.36M | 37.75M | 37.93M | 12.09M |
| Net receivables | 6.71M | 1.65M | 2.44M | 0.19M | 3.00M |
| Long term debt | 7.81M | 13.04M | - | - | - |
| Inventory | 5.49M | 0.00M | - | 0.34M | - |
| Accounts payable | 7.89M | 3.44M | 1.86M | 1.81M | 4.33M |
| Accumulated other comprehensive income | 0.14M | 0.01M | -0.07M | -0.13M | -0.03M |
| Non currrent assets other | 0.78M | 0.10M | 0.28M | 0.04M | 1.06M |
| Non current assets total | 14.66M | 8.08M | 8.26M | 11.12M | 24.18M |
| Capital lease obligations | 4.93M | 4.08M | 5.40M | 7.63M | 9.38M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -39.36M | -39.24M | 0.21M | -23.96M | 66.06M |
| Change to liabilities | - | - | - | -5.49M | 0.82M |
| Total cashflows from investing activities | 105.03M | -39.24M | 0.21M | -23.96M | 66.06M |
| Net borrowings | 0.00M | 20.00M | 0.00M | - | - |
| Total cash from financing activities | 26.04M | 104.14M | 37.06M | 43.17M | 24.86M |
| Change to operating activities | - | - | - | - | -16.09M |
| Net income | 71.18M | -63.73M | -54.19M | -39.70M | -84.94M |
| Change in cash | 54.74M | 8.88M | 0.26M | -24.27M | 25.26M |
| Begin period cash flow | 23.70M | 14.81M | 14.55M | 38.83M | 13.57M |
| End period cash flow | 78.44M | 23.70M | 14.81M | 14.55M | 38.83M |
| Total cash from operating activities | -76.33M | -56.02M | -37.01M | -43.48M | -65.67M |
| Issuance of capital stock | 17.30M | 85.63M | 37.39M | 69.43M | 25.48M |
| Depreciation | 3.56M | 2.91M | 3.20M | 4.58M | 4.46M |
| Other cashflows from investing activities | 152.37M | 0.02M | 0.20M | - | - |
| Change to inventory | -5.49M | 0.00M | - | - | -16.08M |
| Change to account receivables | -5.06M | 0.79M | -2.04M | 3.00M | -3.00M |
| Sale purchase of stock | - | - | -0.18M | -26.25M | - |
| Other cashflows from financing activities | -0.04M | -1.49M | -0.15M | 22.46M | -0.62M |
| Change to netincome | - | - | - | - | 33.07M |
| Capital expenditures | 7.97M | 2.45M | 0.33M | 0.13M | 4.15M |
| Change in working capital | -5.39M | -4.38M | -1.79M | -5.89M | -18.26M |
| Stock based compensation | 10.78M | 6.63M | 4.77M | 3.05M | 8.92M |
| Other non cash items | -156.46M | 2.57M | 11.00M | -5.52M | -6.55M |
| Free cash flow | -84.30M | -58.46M | -37.34M | -43.61M | -69.82M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ABEO Abeona Therapeutics Inc |
0.14 3.25% |
4.45 | - | 18.66 | 12.26 | 2.45 | 7.30 | 3.82 |
| NVO Novo Nordisk A/S |
-0.46 1.18% |
38.67 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
3.54 0.68% |
521.03 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
8.43 1.04% |
816.10 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
790.15 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.
6555 Carnegie Avenue, Cleveland, OH, United States, 44103
646 813 4701
226
| Name | Title | Year Born |
|---|---|---|
| Dr. Vishwas Seshadri M.B.A., Ph.D. | Pres, CEO & Director | 1976 |
| Dr. Brendan M. O'Malley J.D., Ph.D. | Sr. VP & Gen. Counsel | 1969 |
| Mr. Joseph Walter Vazzano | Chief Financial Officer | 1984 |
| Mr. Brian Kevany Ph.D. | VP, CTO & Head of Research | NA |
| Mr. Gregory Gin | VP of Investor Relations & Corp. Communications | NA |
| Scott Santiamo | Director of Corp. Communications | NA |
| Ms. Alison Hardgrove | VP of HR | NA |
| Mr. Jon Voss | VP & Head of Quality | 1960 |
| Dr. Vishwas Seshadri M.B.A., Ph.D. | President, CEO & Director | 1977 |
| Mr. Joseph Walter Vazzano CPA | Chief Financial Officer | 1985 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+1.59%
Communication Services
+0.05%
Consumer Cyclical
+0.14%
Consumer Defensive
-0.43%
Energy
-0.03%
Financial Services
+0.19%
Financials
-0.35%
Healthcare
+1.05%
Industrials
+0.67%
Real Estate
-0.25%
Technology
+1.31%
Utilities
+0.32%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...